Skip to search formSkip to main contentSkip to account menu

motexafin gadolinium

Known as: Gd (III) Texaphryin, Gadolinium Texaphyrin, Gd(III) texaphyrin 
A synthetic metallotexaphyrin with radiosensitizing and chemosensitizing properties. Motexafin gadolinium accumulates in tumor cells preferentially… 
National Institutes of Health

Related topics

Related topics

10 relations

Broader (4)

Antineoplastic AgentsContrast MediaMetalloporphyrinsPhotosensitizing Agents
DNA Breaks, Double-StrandedFree Radical FormationPositive Regulation of Apoptosischemosensitization/potentiation

Narrower (1)

Xcytrin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Clinical development of photodynamic agents and therapeutic applications
BackgroundPhotodynamic therapy (PDT) is photo-treatment of malignant or benign diseases using photosensitizing agents, light, and… 
Review
2012
Review
2012
Treatment of brain metastases: review of phase III randomized controlled trials.
Review
2010
Review
2010
Macromolecules, dendrimers, and nanomaterials in magnetic resonance imaging: the interplay between size, function, and pharmacokinetics.
Magnetism in medicine has had a long and interesting history. In the 10 th century A.D., Egyptian physician and philosopher… 
Highly Cited
2006
Highly Cited
2006
Motexafin Gadolinium, a Tumor-selective Drug Targeting Thioredoxin Reductase and Ribonucleotide Reductase*
Motexafin gadolinium (MGd) is a chemotherapeutic drug that selectively targets tumor cells and mediates redox reactions… 
Review
2004
Review
2004
Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial.
PURPOSE To report the neurocognitive findings in a phase III randomized trial evaluating survival and neurologic and… 
Review
2004
Review
2004
The emerging role of reactive oxygen species in cancer therapy.
  • M. Renschler
  • European Journal of Cancer
  • 2004
  • Corpus ID: 13587006
Review
2003
Review
2003
Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases.
PURPOSE This phase III randomized trial evaluated survival as well as neurologic and neurocognitive function in patients with… 
Highly Cited
1999
Highly Cited
1999
In vivo animal studies with gadolinium (III) texaphyrin as a radiation enhancer.
Highly Cited
1996
Highly Cited
1996
Gadolinium(III) texaphyrin: a tumor selective radiation sensitizer that is detectable by MRI.
Gadolinium(III) texaphyrin (Gd-tex2+) is representative of a new class of radiation sensitizers detectable by magnetic resonance… 
Highly Cited
1996
Highly Cited
1996
Lutetium Texaphyrin (PCI‐0123): A Near‐Infrared, Water‐Soluble Photosensitizer
Lutetium texaphyrin, PCI‐0123, is a pure, water‐soluble photosensitizer with a large broad absorption band centered at 732 nm… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)